IL1B and neoplasm: However we believe that the anti-tumor immune response associated with IL-1α/IL-1 signaling can promote an environment which would be beneficial for the success of select agents that trigger anti-tumor immune responses (including cetuximab, anti-PD1) and further studies are ongoing to investigate these ideas.